Literature DB >> 3919752

Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

U Klotz, T Duka, R Dorow, A Doenicke.   

Abstract

Following a single intravenous dose of 0.1 mg/kg, the pharmacokinetics of Ro 15-1788, a specific benzodiazepine antagonist, have been investigated in 20 healthy male volunteers. In random order injection of Ro 15-1788 has been preceded (5 min) by intravenous dosing with 0.06 mg/kg of lormetazepam (n = 6), 0.03 mg/kg of flunitrazepam (n = 8) or placebo (n = 6). The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min. These single dose studies indicate that the disposition of Ro 15-1788 was not affected by the acute coadministration of both benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919752      PMCID: PMC1463785          DOI: 10.1111/j.1365-2125.1985.tb02619.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Intravenous anaesthesia with a new benzodiazepine Ro 5-4200.

Authors:  J Stovner; R Endresen; A Osterud
Journal:  Acta Anaesthesiol Scand       Date:  1973       Impact factor: 2.105

2.  Aminophylline antagonises diazepam sedation.

Authors:  S B Arvidsson; B Ekström-Jodal; S A Martinell; D Niemand
Journal:  Lancet       Date:  1982-12-25       Impact factor: 79.321

3.  Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.

Authors:  A Darragh; R Lambe; M Scully; I Brick; C O'Boyle; W W Downe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

4.  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.

Authors:  U Klotz; G Ziegler; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.

Authors:  A Darragh; R Lambe; M Kenny; I Brick; W Taaffe; C O'Boyle
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

6.  [The antagonistic effect of physostigmine on sedation by lormetazepam (author's transl)].

Authors:  B Grote; A Doenicke; J Kugler; M Laub; H Ott; K Fichte; H Suttmann; P Zwisler
Journal:  Anaesthesist       Date:  1981-12       Impact factor: 1.041

7.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

8.  Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences.

Authors:  J Kanto; U Klotz
Journal:  Acta Anaesthesiol Scand       Date:  1982-12       Impact factor: 2.105

9.  Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam.

Authors:  U A Pandit; S P Kothary; S K Samra; E F Domino; S K Pandit
Journal:  Anesth Analg       Date:  1983-07       Impact factor: 5.108

10.  [The hypnotic effect of the new benzodiazepine derivative lormetazepam when given intravenously (author's transl)].

Authors:  A Doenicke; J Kugler; M Kropp; M Laub; G Kalbfleisch
Journal:  Anaesthesist       Date:  1979-12       Impact factor: 1.041

View more
  10 in total

1.  Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?

Authors:  U Klotz; G Ziegler; B Rosenkranz; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  Pharmacokinetics of flumazenil in fulminant hepatic failure.

Authors:  C C van der Rijt; R H Drost; S W Schalm; M Schramel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 4.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

5.  Reversal of central benzodiazepine effects by intravenous flumazenil.

Authors:  M S Clark; J E Lindenmuth; B W Jafek; G E Fryer; J R Goldberg
Journal:  Anesth Prog       Date:  1991 Jan-Feb

Review 6.  Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 7.  Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology.

Authors:  R Amrein; B Leishman; C Bentzinger; G Roncari
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

8.  Changes in noradrenaline plasma levels and behavioural responses induced by benzodiazepine agonists with the benzodiazepine antagonist Ro 15-1788.

Authors:  T Duka; M Ackenheil; J Noderer; A Doenicke; R Dorow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 9.  Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).

Authors:  U Klotz; J Kanto
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 10.  Dependence liability of lormetazepam: are all benzodiazepines equal? The case of the new i.v. lormetazepam for anesthetic procedures.

Authors:  Reinhard Horowski
Journal:  J Neural Transm (Vienna)       Date:  2020-05-28       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.